The high expression of FAS in human cancer and its association with poorer prognoses in breast[3], ovarian[4] and prostate carcinomas[5] suggest that high levels of FAS expression and activity provide an advantage for tumor growth and progression. This evidence concerns the gene FAS and prostate carcinoma.